2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial

Pirkko-Liisa Kellokumpu-Lehtinen; Ulrika Harmenberg; Timo Joensuu; Ray McDermott; Petteri Hervonen; Claes Ginman; Marjaana Luukkaa; Paul Nyandoto; Akseli Hemminki; Sten Nilsson; John McCaffrey; Raija Asola; Taina Turpeenniemi-Hujanen; Fredrik Laestadius; Tiina Tasmuth; Katinka Sandberg; Maccon Keane; Ilari Lehtinen; Tiina Luukkaala; Heikki Joensuu; PROSTY Study Grp

doi:10.1016/S1470-2045(12)70537-5

2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial

Pirkko-Liisa Kellokumpu-Lehtinen, Ulrika Harmenberg, Timo Joensuu, Ray McDermott, Petteri Hervonen, Claes Ginman, Marjaana Luukkaa, Paul Nyandoto, Akseli Hemminki, Sten Nilsson, John McCaffrey, Raija Asola, Taina Turpeenniemi-Hujanen, Fredrik Laestadius, Tiina Tasmuth, Katinka Sandberg, Maccon Keane, Ilari Lehtinen, Tiina Luukkaala, Heikki JoensuuPROSTY Study Grp

Forskningsoutput: Tidskriftsbidrag › Artikel › Vetenskaplig › Peer review

Originalspråk	engelska
Tidskrift	Lancet Oncology
Volym	14
Nummer	2
Sidor (från-till)	117-124
Antal sidor	8
ISSN	1470-2045
DOI	https://doi.org/10.1016/S1470-2045(12)70537-5
Status	Publicerad - feb. 2013
MoE-publikationstyp	A1 Tidskriftsartikel-refererad

Vetenskapsgrenar

3122 Cancersjukdomar

Åtkomst av dokument

10.1016/S1470-2045(12)70537-5

Citera det här

Kellokumpu-Lehtinen, P.-L., Harmenberg, U., Joensuu, T., McDermott, R., Hervonen, P., Ginman, C., Luukkaa, M., Nyandoto, P., Hemminki, A., Nilsson, S., McCaffrey, J., Asola, R., Turpeenniemi-Hujanen, T., Laestadius, F., Tasmuth, T., Sandberg, K., Keane, M., Lehtinen, I., Luukkaala, T., ... PROSTY Study Grp (2013). 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncology, 14(2), 117-124. https://doi.org/10.1016/S1470-2045(12)70537-5

@article{dd7f6eb9658541e48237108847725cad,

title = "2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial",

keywords = "MITOXANTRONE PLUS PREDNISONE, ESTRAMUSTINE, GUIDELINES, SAFETY, 3122 Cancers",

author = "Pirkko-Liisa Kellokumpu-Lehtinen and Ulrika Harmenberg and Timo Joensuu and Ray McDermott and Petteri Hervonen and Claes Ginman and Marjaana Luukkaa and Paul Nyandoto and Akseli Hemminki and Sten Nilsson and John McCaffrey and Raija Asola and Taina Turpeenniemi-Hujanen and Fredrik Laestadius and Tiina Tasmuth and Katinka Sandberg and Maccon Keane and Ilari Lehtinen and Tiina Luukkaala and Heikki Joensuu and {PROSTY Study Grp}",

year = "2013",

month = feb,

doi = "10.1016/S1470-2045(12)70537-5",

language = "English",

volume = "14",

pages = "117--124",

journal = "Lancet Oncology",

issn = "1470-2045",

publisher = "EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC",

number = "2",

}

Kellokumpu-Lehtinen, P-L, Harmenberg, U, Joensuu, T, McDermott, R, Hervonen, P, Ginman, C, Luukkaa, M, Nyandoto, P, Hemminki, A, Nilsson, S, McCaffrey, J, Asola, R, Turpeenniemi-Hujanen, T, Laestadius, F, Tasmuth, T, Sandberg, K, Keane, M, Lehtinen, I, Luukkaala, T, Joensuu, H & PROSTY Study Grp 2013, '2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial', Lancet Oncology, vol. 14, nr. 2, s. 117-124. https://doi.org/10.1016/S1470-2045(12)70537-5

TY - JOUR

T1 - 2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial

AU - Kellokumpu-Lehtinen, Pirkko-Liisa

AU - Harmenberg, Ulrika

AU - Joensuu, Timo

AU - McDermott, Ray

AU - Hervonen, Petteri

AU - Ginman, Claes

AU - Luukkaa, Marjaana

AU - Nyandoto, Paul

AU - Hemminki, Akseli

AU - Nilsson, Sten

AU - McCaffrey, John

AU - Asola, Raija

AU - Turpeenniemi-Hujanen, Taina

AU - Laestadius, Fredrik

AU - Tasmuth, Tiina

AU - Sandberg, Katinka

AU - Keane, Maccon

AU - Lehtinen, Ilari

AU - Luukkaala, Tiina

AU - Joensuu, Heikki

AU - PROSTY Study Grp

PY - 2013/2

Y1 - 2013/2

KW - MITOXANTRONE PLUS PREDNISONE

KW - ESTRAMUSTINE

KW - GUIDELINES

KW - SAFETY

KW - 3122 Cancers

U2 - 10.1016/S1470-2045(12)70537-5

DO - 10.1016/S1470-2045(12)70537-5

M3 - Article

SN - 1470-2045

VL - 14

SP - 117

EP - 124

JO - Lancet Oncology

JF - Lancet Oncology

IS - 2

ER -